XFOR Stock Based Compensation vs Capital Expenditures Analysis
XFOR Stock | USD 0.61 0.03 4.69% |
X4 Pharmaceuticals financial indicator trend analysis is more than just analyzing X4 Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether X4 Pharmaceuticals is a good investment. Please check the relationship between X4 Pharmaceuticals Stock Based Compensation and its Capital Expenditures accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.
Stock Based Compensation vs Capital Expenditures
Stock Based Compensation vs Capital Expenditures Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of X4 Pharmaceuticals Stock Based Compensation account and Capital Expenditures. At this time, the significance of the direction appears to have almost no relationship.
The correlation between X4 Pharmaceuticals' Stock Based Compensation and Capital Expenditures is 0.19. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of X4 Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of X4 Pharmaceuticals' Stock Based Compensation and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of X4 Pharmaceuticals are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Stock Based Compensation i.e., X4 Pharmaceuticals' Stock Based Compensation and Capital Expenditures go up and down completely randomly.
Correlation Coefficient | 0.19 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Capital Expenditures
Capital Expenditures are funds used by X4 Pharmaceuticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of X4 Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most indicators from X4 Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into X4 Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.As of 12/22/2024, Enterprise Value is likely to grow to about 130.6 M, while Selling General Administrative is likely to drop slightly above 19.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Depreciation And Amortization | 1.9M | 2.0M | 419K | 398.1K | Interest Income | 10K | 219K | 3.3M | 3.5M |
X4 Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
X4 Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
X4 Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 160.7M | 122.9M | 117.2M | 155.6M | 147.3M | 102.4M | |
Short Long Term Debt Total | 22.9M | 38.4M | 39.8M | 38.4M | 58.3M | 29.6M | |
Other Current Liab | 6.5M | 7.2M | 6.8M | 10.8M | 11.7M | 6.9M | |
Total Current Liabilities | 9.4M | 11.9M | 14.0M | 22.3M | 22.9M | 13.7M | |
Total Stockholder Equity | 129.2M | 72.8M | 64.4M | 74.1M | 51.1M | 46.6M | |
Property Plant And Equipment Net | 2.4M | 9.2M | 10.2M | 8.3M | 6.4M | 4.7M | |
Net Debt | (103.3M) | (40.3M) | (42.0M) | (83.3M) | (40.9M) | (43.0M) | |
Retained Earnings | (132.0M) | (194.2M) | (282.9M) | (376.7M) | (477.9M) | (454.0M) | |
Accounts Payable | 2.1M | 3.1M | 4.3M | 7.8M | 8.9M | 9.4M | |
Cash | 126.2M | 78.7M | 81.8M | 121.7M | 99.2M | 76.4M | |
Non Current Assets Total | 31.4M | 39.6M | 29.3M | 26.9M | 25.2M | 19.2M | |
Non Currrent Assets Other | 1.9M | 3.3M | 1.7M | 1.2M | 1.4M | 1.6M | |
Cash And Short Term Investments | 126.2M | 78.7M | 81.8M | 121.7M | 114.2M | 78.2M | |
Net Receivables | 2.0M | 917K | 747K | 1.2M | 562K | 533.9K | |
Common Stock Shares Outstanding | 11.5M | 20.1M | 25.7M | 63.5M | 177.8M | 186.7M | |
Liabilities And Stockholders Equity | 160.7M | 122.9M | 117.2M | 155.6M | 147.3M | 102.4M | |
Non Current Liabilities Total | 22.0M | 38.1M | 38.7M | 59.2M | 73.3M | 42.1M | |
Other Current Assets | 1.1M | 3.7M | 5.3M | 5.8M | 7.3M | 7.7M | |
Other Stockholder Equity | 100.7M | 267.1M | 347.4M | 450.8M | 529.0M | 555.4M | |
Total Liab | 31.5M | 50.1M | 52.8M | 81.5M | 96.2M | 55.9M | |
Property Plant And Equipment Gross | 2.4M | 9.2M | 10.2M | 8.3M | 8.0M | 4.9M | |
Total Current Assets | 129.3M | 83.3M | 87.9M | 128.7M | 122.1M | 83.3M | |
Short Term Debt | 898K | 1.6M | 2.9M | 3.7M | 2.2M | 2.0M | |
Other Liab | 16K | 462K | 826K | 23.3M | 26.8M | 28.1M | |
Net Tangible Assets | 102.1M | 45.7M | 47.1M | 56.7M | 65.2M | 68.5M | |
Long Term Debt | 20.1M | 33.2M | 33.1M | 32.3M | 54.6M | 27.7M | |
Short Long Term Debt | 2.3M | 1.7M | 795K | 1.3M | 1.2M | 1.8M | |
Non Current Liabilities Other | 16K | 462K | 826K | 3.6M | 432K | 748K | |
Property Plant Equipment | 2.4M | 9.2M | 10.2M | 1.1M | 1.3M | 1.2M | |
Capital Surpluse | 156.6M | 261.4M | 267.1M | 450.8M | 518.4M | 283.1M | |
Net Invested Capital | 149.3M | 106.0M | 98.3M | 107.7M | 105.7M | 104.9M | |
Net Working Capital | 119.8M | 71.4M | 73.9M | 106.4M | 99.2M | 89.4M |
Pair Trading with X4 Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against XFOR Stock
0.6 | VANI | Vivani Medical | PairCorr |
0.4 | DRUG | Bright Minds Biosciences | PairCorr |
0.32 | VERA | Vera Therapeutics | PairCorr |
0.31 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.